Clinical Trial Update: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for furmonertinib in advanced or metastatic non-small cell lung cancer with activating or uncommon EGFR/HER2 mutations; status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: ArriVent BioPharma, Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING